Compare Hut 8 Corp (HUT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Hut 8 CorpTrade

Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Hut 8 Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Hut 8 Corp trades at $105.06 (market cap $11.36B), while Vertex Pharmaceuticals Incorporated trades at $480 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 10.7× Hut 8 Corp's market cap. Which is the better fit depends on your goals.

	HUT	VRTX
Market Cap	$11.36B	$121.95B
Sector	Technology	Health
52-Week High	$133.02	$529.59
52-Week Low	$19.45	$366.54
Enterprise Value	$11.63B	$116.69B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hut 8 Corp

HUT trades at $100.93, up 10.37% in the past 24 hours, with a bearish technical signal from moving averages and oscillators. The company reported a net loss of $226.15 million in 2025 despite revenue of $235.12 million, though it beat EPS estimates in two of the last three quarters. Recent news highlights its pivot to AI infrastructure, including a $4.25 billion bond issuance for data center projects (PRNewsWire, 2026-06-09).

Analyst consensus is strongly bullish with a $138.89 price target, but high valuation ratios and persistent losses pose risks. The stock's outlook hinges on successful execution of its digital infrastructure strategy, though cash flow challenges and competitive pressures remain key concerns for investors.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $480.51, down 1.06% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a 35.51% net income margin and robust cash flow, though it faces a recent earnings miss. A major $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio, adding potential for significant future revenue growth.

The outlook remains positive with an 85.71% analyst buy rating and a $538 consensus price target, implying 12% upside. Key risks include integration challenges from the acquisition and reliance on cystic fibrosis treatments. Earnings growth and successful pipeline execution are critical catalysts for sustained appreciation.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

HUT

Hut 8 Mining signs $9.8B lease, AMC beats Q2 estimates, Replenish Nutrients secures $15M investmentProactive Investors · 20 hours agoBullish Hut 8 signs $9.8B lease to expand AI data center capacity, Needham raises price target to $145Tony Dante · 21 hours agoBullish Hut 8 doubles AI data center lease capacity to 704 MW with $9.8B 15-year contract at Beacon Point campusPRNewsWire · 1 day agoBullish View details →

VRTX

View details →

About Hut 8 Corp

Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.